Initial human safety and tolerance study of a GABA uptake inhibitor, Cl‐966: Potential role of GABA as a mediator in the pathogenesis of schizophrenia and mania
- 1 January 1990
- journal article
- research article
- Published by Wiley in Drug Development Research
- Vol. 21 (3), 235-242
- https://doi.org/10.1002/ddr.430210309
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- GABA uptake inhibitors: relevance to antiepileptic drug researchEpilepsy Research, 1987
- Anticonvulsant action in the epileptic gerbil of novel inhibitors of GABA uptakeEuropean Journal of Pharmacology, 1985
- Effects of THIP on chronic anxietyPsychopharmacology, 1983
- Current perspectives in the pharmacopsychiatry of depression and maniaNeuropharmacology, 1983
- The Interaction Between GABA and Dopamine: Implications for SchizophreniaSchizophrenia Bulletin, 1983
- The potential use of GABA agonists in psychiatric disorders: Evidence from studies with progabide in animal models and clinical trials1Pharmacology Biochemistry and Behavior, 1983
- On the therapeutic action of SL 76 002, a new GABA-mimetic agent: Preliminary observations in neuropsychiatric disordersBrain Research Bulletin, 1980
- Sodium Valproate in Schizophrenia: Some Biochemical CorrelatesThe British Journal of Psychiatry, 1980
- Medical Treatment of Mental IllnessScience, 1978
- BACLOFEN IN SCHIZOPHRENIAThe Lancet, 1976